Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The invertebrate gamma-aminobutyric acid (GABA)-gated chloride channel is a member of the Cys-loop superfamily of ligand-gated ion channels and serves as the primary mediator of inhibitory neurotransmission in the central nervous system of insects and other invertebrates (Raymond-Delpech et al., 2005, PMID: 16135011). Upon binding of the neurotransmitter GABA, the channel undergoes a conformational change that allows the influx of chloride ions, leading to hyperpolarization of the postsynaptic neuron and suppression of neuronal excitability. This receptor is a critical target for various classes of insecticides and ectoparasiticides, including phenylpyrazoles like fipronil and the newer isoxazoline class such as fluralaner (Casida & Durkin, 2013, PMID: 23356357). These compounds typically act as non-competitive antagonists by binding within the channel pore or at allosteric sites, thereby blocking chloride conductance and causing hyperexcitation, convulsions, and death in the target organism (Weber & Selzer, 2016, PMID: 27130457). Because of structural differences between invertebrate and mammalian GABA receptors, these channels offer a high degree of selective toxicity, making them invaluable in veterinary medicine for treating flea and tick infestations and in agriculture for pest control (Gassel et al., 2014, PMID: 24703460). Resistance to these drugs often arises through specific mutations in the RDL (Resistance to dieldrin) gene, which encodes the channel subunit (Ffrench-Constant et al., 2000, PMID: 10890351).
Non-competitive antagonism of the chloride channel pore and allosteric inhibition (IRAC Group 2 and Group 30) (Casida & Durkin, 2013, PMID: 23356357)
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Invertebrate gamma-aminobutyric acid-gated chloride channel (iGABA-Cl) (iGABA-Cl).